Wound Heal
Conditions
Keywords
surgical wounds, infected wounds
Brief summary
There are currently limited treatments available that show anti-biofilm efficacy for wound infection management Biofilms account for over 80% of infections and approximately 65% of nosocomial infections caused by microorganisms in the developed world involve biofilms. There clearly is a need for cost effective, highly stable, easily obtained biofilm targeted strategies for treatment of chronic wound biofilm infections. The information generated from this project has the potential of providing considerable benefits to wound care by determining the efficacy of EDT dressing in managing wound biofilm infection and efficacy in wound healing and closure. Such knowledge could help therapeutic strategies and could provide information for future clinical studies to further understanding -of EDT wound dressings.
Detailed description
This is a randomized open-label clinical study to test the efficacy of the treatment protocol using an optimized EDThi & EDTlo sequential approach in infected or high risk of infection burn/trauma/surgery chronic wounds against biofilm infection. This trial will determine the efficacy of EDT dressing against wound biofilm infection. subjects will be randomized to one of the two groups: 1) standard of care (SoC) only and 2) SoC + EDT dressing treatment. In group 2, in addition to SoC, the patients will apply the EDThi dressing (PED-10) on the wound(s) for the first 3 weeks following enrollment followed by Procellera® for additional 3 weeks. The use of dressings will be discontinued anytime if complete wound closure is achieved.
Interventions
DEVICEElectroceutical Dressing Technology-EDThi
Use of EDThi for 3 weeks post enrollment
DEVICEAdding EDTlo (Procellera®) for 3 weeks after use of EDThi
Use of EDTlo (Procellera®) for additional 3 weeks
Sponsors
United States Department of Defense
Naval Medical Research Center
Indiana University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Masking description
to avoid bias, the personnel performing the biofilm analysis (Primary outcome) will be blinded towards the study groups.
Intervention model description
Participants are assigned to one of two groups in parallel for the duration of the study
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Ages 18 years and older 2. subjects willing and able to provide informed consent 3. patients with infected chronic trauma or surgical wounds 4. wound(s) must be able to be covered by the EDT dressing 5. All patients, with wounds below the knee, must have wound tissue oxygenation adequate to support wound healing per provider discretion, this may be defined by one or more of the following perfusion values within 6 months on enrollment: peri-wound transcutaneous oxygen measurements ≥ 25 mmHg (TCOM),Ankle Brachial Index (ABI) \>0.7, or a Toe pressure (TP) \> 40 mmHg, If none of these tests were performed during standard of care, then a trained study team member may obtain a TCOM measurement after the patient has consented and before they are enrolled. If there are multiple perfusion values that conflict, then a physician will review and determine if they are eligible for enrollment. If a patient has had a recent re-vascularization, the patient may be enrolled once adequate perfusion has been verified. 6. Subjects must be able to read and understand English.
Exclusion criteria
1. Individuals who are deemed unable to understand the procedures, risks and benefits of the study, ie. Informed consent will be excluded 2. Pregnant women 3. Prisoners 4. Wound tissue not available for analysis 5. Patient with known sensitivity or allergic reaction to zinc or silver 6. Current active diagnosis of Osteomyelitis at the target wound site, that is untreated, based on clinical diagnosis per EMR.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Response to the use of EDT treatment in prevention of wound biofilm infection | 6 weeks | Impact of EDT treatment in prevention of incidence of wound biofilm infection |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| rate of wound closure 6 weeks post-treatment as compared to baseline | 6 weeks | rate of wound closure 6 weeks post-treatment as compared to baseline |
| wound microbiome in SoC and SoC+ EDT treatment. | 3 weeks | presence of microbiome in standard of care with and w/o treatment |
| Percent of patients with response to EDT treatment on week 6 as compared to SoC only group | 6 weeks | Percent of patients showing treatment response on week 6 comparing SOC group to ntervention group |
Countries
United States
Outcome results
None listed